- Article metrics
- Last updated: Mon, 13 Oct 2025 3:54:59 Z
Digoxin for reduction of circulating tumor cell cluster size in metastatic breast cancer: a proof-of-concept trial
Access & Citations
-
- 27k
- Article Accesses
-
- 27
- Citations
Citation counts are provided by Dimensions and depend on their data availability. Counts will update daily, once available.
Online attention
- 205 tweeters
- 2 blogs
- 60 news outlets
- 1 Wikipedia page
- 41 Mendeley
This article is in the 99th percentile (ranked 707th) of the 366,649 tracked articles of a similar age in all journals and the 92nd percentile (ranked 16th) of the 212 tracked articles of a similar age in Nature Medicine
View more on Altmetric
Altmetric calculates a score based on the online attention an article receives. Each coloured thread in the circle represents a different type of online attention. The number in the centre is the Altmetric score. Social media and mainstream news media are the main sources that calculate the score. Reference managers such as Mendeley are also tracked but do not contribute to the score. Older articles often score higher because they have had more time to get noticed. To account for this, Altmetric has included the context data for other articles of a similar age.
Mentions in news and blogs
-
Im Kampf gegen Brustkrebs: Uralt-Herzmedikament Digoxin löst Tumorzell-Haufen auf
Salzburger Nachrichten -
Krebszell-Cluster auflösen, um Metastasen zu verhindern
Informationsdienst Wissenschaft -
Breakthrough study targets tumor cell clusters to prevent metastasis
The Medical News -
Breakthrough study targets tumor cell clusters to prevent metastasis
news-medical.net -
Existing cardiac drug helps keep cancer from spreading
Gizmag Emerging Technology Magazine
This list highlights individual mainstream news articles and blogs that cite the article. Not all news and blogs link to articles in a way that Altmetric can pick up, so they are not representative of all media. Altmetric are responsible for the curation of this list and provide updates hourly.